* Only samples with a positive ACTB call were included, as only these were used in the analyses.
Supplemental Table 2 . Seventy-eight MSP assays were designed, technically validated and tested for overall and event-free survival prediction. For each assay, if available, the gene annotation is shown, as well as the forward and reverse primer (5' to 3'), and the genomic location of the amplicon on the hg19 reference genome. The corresponding region of interest in the methyl-CpG-binding domain sequencing data and the comparisons in which the region was identified as differentially methylated (indicated by yes, followed by the group that is hypermethylated) are indicated, as well as log-rank p-values for overall and event-free survival in the corresponding test cohort. Furthermore, it is shown whether the assay is part of the 58-marker signature or not.
Supplemental Table 3 Supplemental Table 5 . The 58-marker methylation signature is an independent prognostic predictor of overall survival in MSP cohort II. For each variable, the p-value, odds ratio (OR) and 95% confidence interval (CI) of the univariable and multivariable logistic regression analyses are shown. The age at diagnosis cutoff is 18 months.
